- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT03343249
Adjunctive Smart Phone Based Smoking Cessation Treatment
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Research Supporting Study Objectives. Tobacco use is the leading cause of preventable death in the U.S. Over 443,000 deaths per year are attributable to smoking, with the leading causes of smoking-attributable death being cancer, cardiovascular diseases, and respiratory disease. Although the prevalence of smoking has declined to 20.6% among U.S. adults, 31.1% of those living in poverty are currently smoking. Numerous studies have shown that low SES and financial strain are associated with a reduced likelihood of smoking cessation. As such, lung cancer incidence is far greater among those with low education and who are living in poverty, relative to their higher SES counterparts. Although individuals of low SES are just as likely to attempt smoking cessation, they are less likely to succeed. As such, smoking cessation interventions for low SES populations have had limited success (e.g., biologically confirmed 7-day point prevalence abstinence rates of 7-13% at 6-month follow-up. Innovative smoking cessation interventions are needed to help reduce the rate of smoking in socioeconomically disadvantaged populations of smokers.
Ecological Momentary Assessment and Smoking Cessation Treatments. To date, most studies that have examined smoking and smoking cessation in socioeconomically disadvantaged smokers have used focus groups or traditional lab/clinic based assessment methodology. In the latter scenario, study participants arrive at a lab or clinic for their baseline visit and are asked to answer questions about their "average" or "recent" (e.g., over the past 2 weeks) mood, level of stress, and smoking urges. Participants return to the lab/clinic for follow-up visits and are asked to report thoughts, feelings, and activities that occurred weeks or even months earlier (e.g., "How stressed were you when you smoked your first cigarette after your quit date?"). This type of assessment methodology may result in biased and/or inaccurate estimates due to recall biases and errors in memory and only offers a gross understanding of how cessation symptoms effect smoking lapses and relapse. A more nuanced picture of these symptoms may offer important insights that may be used to create or improve cessation interventions for socioeconomically disadvantaged smokers, who face unique and substantial challenges in quitting smoking.
Ecological momentary assessment (EMA), in which handheld devices (e.g., smart phones) are used to capture moment to moment experience, is currently the most accurate way to measure phenomena in real time in natural settings. EMAs are often used to assess individuals at multiple time points throughout a day. Thus, momentary changes in key variables can be tracked and potentially used to initiate novel interventions. EMA research may facilitate a better understanding of the mechanisms involved in successful cessation attempts, those affecting smoking lapses, and those implicated in the transition from lapse to relapse. Although multiple studies have identified momentary predictors of smoking relapse to our knowledge, no studies have used a participant's responses to EMAs to automatically prompt tailored smoking cessation interventions. Using smart phones to detect high relapse risk situations and automatically deliver tailored smoking cessation treatments may help socioeconomically disadvantaged smokers quit.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Participants will be included in the study if they:
- earn a score greater than or equal to 4 on the Short REALM indicating greater than 6th grade English literacy level,
- are willing to quit smoking 7 days from their first visit,
- are greater than or equal to 18 years of age,
- have an expired CO level greater than or equal to 8 ppm suggestive of current smoking,
- are currently smoking greater than or equal to 5 cigarettes per day,
- are willing and able to attend 6 weekly sessions (i.e., week -1, quit day, week +1, week +2, week +3, week +4) and the 12 week follow-up session , and
- have not previously participated in Project PREVAIL [STU 042011-096] at Parkland Hospital. Please note that the Parkland smoking cessation program (usual care) is currently offered in English only.
Exclusion Criteria:
Participants will be excluded from the study if they:
- are unwilling to quit smoking 7 days from their first visit,
- have already quit smoking,
- earn a score less than 4 on the Short REALM indicating less than or equal to 6th grade literacy level,
- produce an expired CO level less than 8 ppm,
- are currently smoking less than 5 cigarettes per day,
- are unwilling or unable to attend 7 assessment sessions,
- are less than 18 years of age, and/or
- have not previously participated in Project PREVAIL [STU 042011-096] at Parkland Hospital. Please note that the Parkland smoking cessation program (usual care) is currently offered in English only.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Study Visits
The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured. Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete. |
The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system.
The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time.
The phone has 4G and is Wi-Fi and GPS capable.
Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire.
Thus, computer/typing skills are not required.
Participants have the ability to call and receive calls from research staff through the smart phone free of charge.
All phones will be equipped with Global Positioning Systems (GPS) capability.
The smart phones are also equipped with a Secure Digital card to store data as it is collected.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Smoking abstinence
Ramy czasowe: 12 weeks
|
Evidence of abstinence from smoking confirmed by questionnaire.
|
12 weeks
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Jennifer Gonzalez, UT Southwestern Medical Center
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- SCCC-PSO1Z14
- STU 012014-012 (Inny identyfikator: UTSouthwestern Medical Center)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak wysokiego ryzyka
-
University of ChicagoJeszcze nie rekrutacjaHER2 Pozytywne nowo zdiagnozowane przerzuty przełyku, żołądka, GEJ Cancer Pacjenci ze statusem wydajności ECOG 2
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)Jeszcze nie rekrutacjaSyndrom Lyncha | Dziedziczny zespół nowotworowy | BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome | BRCA2-Related Hereditary Breast and Ovarian Cancer SyndromeStany Zjednoczone
-
Cothera Bioscience, IncAktywny, nie rekrutującyChłoniak z komórek B | Chłoniak, duże komórki B, rozlany | Choroby limfatyczne | Chłoniak Burkitta | Chłoniak z komórek B wysokiego stopnia | C-MYC/BCL6 Double-Hit High Grade Chłoniak z komórek B | C-MYC/BCL2 Double-Hit High Grade Chłoniak z komórek B | Chłoniak, wysoki stopień | Przegrupowanie genu C-MycRepublika Korei, Chiny
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Patrick C. Johnson, MDAstraZenecaAktywny, nie rekrutującyOporny na leczenie chłoniak nieziarniczy z komórek B | Rozlany chłoniak z dużych komórek B (DLBCL) | Chłoniak grudkowy stopnia 3b | Oporne na leczenie agresywne chłoniaki z komórek B | Agresywny NHL z komórek B | De Novo lub transformowany chłoniak indolentny z komórek B | DLBCL, nr podtypów genetycznych i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.Aktywny, nie rekrutującyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)ZakończonyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
Badania kliniczne na Smart Phone Based Smoking Cessation
-
Northwestern UniversityNational Institutes of Health (NIH); Vibrent HealthWycofane
-
Montefiore Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) i inni współpracownicyRejestracja na zaproszenieDepresja | Toczeń rumieniowaty układowyStany Zjednoczone
-
Lawson Health Research InstituteLondon Health Sciences Centre; St. Joseph's Health Care London; Canadian Mental...ZakończonyZaburzenia nastroju | Zaburzenie psychotyczneKanada